A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).
Multiple Myeloma
DRUG: CC-92480|DRUG: Tazemetostat|DRUG: BMS-986158|DRUG: Trametinib|DRUG: Dexamethasone
Number of participants with adverse events (AEs), From first participant first visit until 28 days after the last participant discontinues study treatment, up to approximately 4 years|Establish recommended Phase 2 dose (RP2D), Up to approximately 2 years|Establish dosing schedule of each combination for Part 2 Dose Expansion, Up to approximately 2 years
Overall response rate (ORR), Up to approximately 4 years|Very good partial response rate (VGPRR), Up to approximately 4 years|Complete response rate (CRR), Up to approximately 4 years|Time-to-response (TTR), Up to approximately 4 years|Duration of response (DOR), Up to approximately 4 years|Progression-free survival (PFS), Up to approximately 4 years|Maximum observed plasma concentration (Cmax), Up to approximately 28 days|Time to maximum plasma concentration (Tmax), Up to approximately 28 days|Area under the concentration-time curve (AUC), Up to approximately 28 days
The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).